164 related articles for article (PubMed ID: 11012295)
21. Candida endophthalmitis: focus on current and future antifungal treatment options.
Khan FA; Slain D; Khakoo RA
Pharmacotherapy; 2007 Dec; 27(12):1711-21. PubMed ID: 18041891
[TBL] [Abstract][Full Text] [Related]
22. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.
Yang YL; Li SY; Cheng HH; Lo HJ;
BMC Infect Dis; 2005 Nov; 5():99. PubMed ID: 16266438
[TBL] [Abstract][Full Text] [Related]
23. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
Krcmery V; Barnes AJ
J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
[TBL] [Abstract][Full Text] [Related]
24. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
25. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
27. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
Yang YL; Li SY; Cheng HH; Lo HJ;
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603
[TBL] [Abstract][Full Text] [Related]
28. Treatment of invasive fungal infections.
Warnock DW
Hosp Med; 1998 Apr; 59(4):266-7. PubMed ID: 9722362
[No Abstract] [Full Text] [Related]
29. New developments in the diagnosis and management of invasive fungal infections.
De Marie S
Haematologica; 2000 Jan; 85(1):88-93. PubMed ID: 10629598
[TBL] [Abstract][Full Text] [Related]
30. Management of systemic fungal infections: alternatives to itraconazole.
Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
[TBL] [Abstract][Full Text] [Related]
31. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.
Playford EG; Marriott D; Nguyen Q; Chen S; Ellis D; Slavin M; Sorrell TC
Crit Care Med; 2008 Jul; 36(7):2034-9. PubMed ID: 18552700
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
Arredondo-García JL; Amábile-Cuevas CF;
J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
[TBL] [Abstract][Full Text] [Related]
33. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
34. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ;
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773
[TBL] [Abstract][Full Text] [Related]
35. [Controversy concerning optimal prophylaxis and empirical antifungal therapy in immunocompromised patients].
Zielińska E
Przegl Epidemiol; 2003; 57(2):299-307. PubMed ID: 12910598
[TBL] [Abstract][Full Text] [Related]
36. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
37. Prevention of systemic mycoses in patients who are not neutropenic: should we do it? Can we do it?
Graybill JR
Braz J Infect Dis; 2000 Jun; 4(3):108-12. PubMed ID: 10934492
[TBL] [Abstract][Full Text] [Related]
38. Fluconazole: a new antifungal agent.
Kowalsky SF; Dixon DM
Clin Pharm; 1991 Mar; 10(3):179-94. PubMed ID: 2040125
[TBL] [Abstract][Full Text] [Related]
39. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review.
Viscoli C; Castagnola E
Int J Infect Dis; 1998-1999 Winter; 3(2):109-18. PubMed ID: 10225990
[TBL] [Abstract][Full Text] [Related]
40. Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium.
Böhme A; Karthaus M
Chemotherapy; 1999; 45(5):315-24. PubMed ID: 10473919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
